Search Results - "Barrera, Jose Cabeza"

Refine Results
  1. 1

    Pharmacogenetics of siponimod: A systematic review by Díaz-Villamarín, Xando, Piñar-Morales, Raquel, Barrero-Hernández, Francisco Javier, Antúnez-Rodríguez, Alba, Cabeza-Barrera, José, Morón-Romero, Rocío

    Published in Biomedicine & pharmacotherapy (01-09-2022)
    “…Multiple sclerosis is a chronic inflammatory neurological disease, and siponimod (Mayzent) is the first oral treatment option for adult patients with secondary…”
    Get full text
    Journal Article
  2. 2

    Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation by Díaz-Villamarín, Xando, Fernández-Varón, Emilio, Rojas Romero, Michelle Carolina, Callejas-Rubio, José Luis, Cabeza-Barrera, José, Rodríguez-Nogales, Alba, Gálvez, Julio, Morón, Rocío

    Published in Biomedicine & pharmacotherapy (01-12-2023)
    “…Azathioprine is commonly used as an immunosuppressive antimetabolite in the treatment of acute lymphoblastic leukemia, autoimmune disorders (such as Crohn's…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate by Hermosilla, Jesús, Alonso-García, Airan, Salmerón-García, Antonio, Cabeza-Barrera, José, Medina-Castillo, Antonio L., Pérez-Robles, Raquel, Navas, Natalia

    Published in Vaccines (Basel) (01-11-2023)
    “…Comirnaty™ and Spikevax™ were the first vaccines approved for human use based on modified non-replicating mRNA lipophilic nanoparticle (mRNA-LNP) technology,…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate by Dávila-Fajardo, Cristina Lucía, Swen, Jesse J, Cabeza Barrera, José, Guchelaar, Henk-Jan

    Published in Pharmacogenomics (01-01-2013)
    “…Low-dose methotrexate (MTX) is part of the mainstay of rheumatoid arthritis treatment. Hepatotoxicity is among the most feared side effects of low-dose MTX and…”
    Get more information
    Journal Article
  10. 10
  11. 11
  12. 12

    Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients by Pérez-Ramírez, Cristina, Cañadas-Garre, Marisa, Molina, Miguel Ángel, Cabeza Barrera, José, Faus-Dáder, María José

    Published in Mutation research (01-07-2019)
    “…EGFR tyrosine kinase inhibitors (EGFR-TKIs) are the treatment of choice for advanced-stage (IIIB-IV) NSCLC patients with mutations in EGFR. However, EGFR-TKIs…”
    Get full text
    Journal Article
  13. 13

    Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes by Caballero Romero, Álvaro, Delgado Ureña, María Teresa, Salmerón García, Antonio, Megías Fernández, María Teresa, Librada Porriño-Bustamante, María, Cabeza Barrera, José

    Published in Anti-cancer drugs (01-10-2018)
    “…The extravasation of chemotherapeutic agents is a challenge for oncologic care teams. The management of nonliposomal (conventional) anthracyclines is well…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18

    Medication reconciliation at admission to surgical departments by González-García, Lorena, Salmerón-García, Antonio, García-Lirola, MªAngeles, Moya-Roldán, Susana, Belda-Rustarazo, Susana, Cabeza-Barrera, José

    Published in Journal of evaluation in clinical practice (01-02-2016)
    “…Rationale, aims and objectives We aim to determine the prevalence of reconciliation errors (REs) at admission to surgery departments, report their potential…”
    Get full text
    Journal Article
  19. 19
  20. 20